OLMAHIGH SIGNALFINANCIAL10-K

OLMA experienced a severe 65% cash burn dropping from $139.5M to $48.3M while operating losses widened significantly to -$162.5M, creating potential liquidity concerns for this clinical-stage biotech.

The dramatic cash decline combined with worsening operating cash flow (-$146.7M vs -$104.4M) suggests OLMA may face funding pressures within the next 12-18 months if burn rates continue. The company appears to have raised capital (evidenced by the share count increase from 68.3M to 87.2M shares plus pre-funded warrants), but the proceeds were insufficient to offset the accelerated cash consumption from expanded R&D activities.

Comparing 2026-03-16 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

OLMA's financial position deteriorated significantly with cash dropping 65% to $48.3M while R&D expenses surged 27% to $157.7M, driving operating losses 26% higher to -$178.7M. Despite raising capital (share count increased ~28% including warrants), the company burned through approximately $91M in cash while liabilities increased 31% to $54.9M. The overall picture signals mounting financial pressure for this clinical-stage company, with accelerating losses and a rapidly depleting cash runway that may necessitate additional financing in the near term.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-65.4%
$139.5M→$48.3M

Cash declined 65.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Capital Expenditure
Cash Flow
-56.2%
$363K→$159K

Capex reduced 56.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
-40.6%
-$104.4M→-$146.7M

Operating cash flow fell 40.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Liabilities
Balance Sheet
+30.6%
$42.0M→$54.9M

Liabilities grew 30.6% — significant increase in debt or obligations, assess impact on financial flexibility.

R&D Expense
P&L
+26.6%
$124.5M→$157.7M

R&D investment increased 26.6% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-25.6%
-$142.3M→-$178.7M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Net Income
P&L
-25.5%
-$129.5M→-$162.5M

Net income declined 25.5% — review whether driven by operations, interest costs, or non-recurring items.

Current Liabilities
Balance Sheet
+24.1%
$41.8M→$51.8M

Current liabilities rose 24.1% — increased short-term obligations, watch current ratio.

Total Assets
Balance Sheet
+18.3%
$451.0M→$533.4M

Asset base grew 18.3% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+17.6%
$438.5M→$515.5M

Current assets grew 17.6% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-18
ADDED
As of March 11, 2026, the number of outstanding shares of the Registrant s common stock was 87,156,961 .
This number does not include 13,594,149 shares of common stock issuable upon the exercise of pre-funded warrants (which are immediately exercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations) (See Notes 2 and 7 to the Registrant's consolidated financial statements).
If we are ultimately unable to obtain regulatory approval for palazestrant, OP-3136, or any future product candidate we may develop, we will be unable to generate product revenue and our business, financial condition, results of operations, and prospects will be significantly harmed.
We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer, or less expensive than palazestrant, OP-3136, or any future product candidates we may develop, our commercial opportunities will be negatively impacted.
or foreign regulatory approvals and, as a result, may be unable to commercialize palazestrant, OP-3136, or any future product candidates we may develop.
and global macroeconomic and geopolitical conditions could adversely affect our business, financial condition, results of operations, and prospects.
If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize palazestrant, OP-3136, or future product candidates we may develop and our business, financial condition, results of operations, and prospects could be significantly harmed.
In clinical studies across more than 400 patients, palazestrant has demonstrated strong anti-tumor activity, attractive pharmacokinetics and prolonged drug exposure, favorable tolerability, and combinability with cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) with no significant drug-drug interaction.
We anticipate top-line results for this trial in the fall of 2026, expect to submit the NDA in 2027, and , if successful, anticipate potential U.S.
Food and Drug Administration (FDA) approval and commercial launch in late 2027.
REMOVED
As of March 13, 2025, the number of outstanding shares of the Registrant s common stock was 68,333,065 .
If we are ultimately unable to obtain regulatory approval for palazestrant or OP-3136, we will be unable to generate product revenue and our business, financial condition, results of operations and prospects will be significantly harmed.
We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than palazestrant, OP-3136 or product candidates we may develop in the future, our commercial opportunities will be negatively impacted.
or foreign regulatory approvals and, as a result, may be unable to commercialize palazestrant, OP-3136 or any future product candidate we may develop.
and global macroeconomic and geopolitical conditions could adversely affect our business, financial condition and results of operations.
We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs to conduct certain aspects of our non-clinical studies and clinical trials.
In clinical studies across more than 400 patients, palazestrant has demonstrated strong anti-tumor activity, attractive pharmacokinetics and prolonged drug exposure, favorable tolerability, and combinability with CDK4/6 inhibitors with no significant drug-drug interaction.
In combination, we are investigating palazestrant in multiple Phase 1/2 studies with CDK4/6 inhibitors (palbociclib or ribociclib), a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor (alpelisib), and with an mTOR inhibitor (everolimus).
In March 2024, we increased the size of the ongoing Phase 1/2 clinical study of palazestrant in combination with ribociclib by an additional 15 patients to explore 90 mg of palazestrant in combination with 600 mg of ribociclib.
We also initiated our Phase 1b/2 clinical study of palazestrant in combination with an mTOR inhibitor, everolimus, in the third quarter of 2024.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →